

Monocentric survey about the use of Raltitrexed in the daily clinical practice for patients with metastatic colorectal cancer.

Original

Monocentric survey about the use of Raltitrexed in the daily clinical practice for patients with metastatic colorectal cancer / Ponzetti, A.; Zaccaria, GIAN MARIA; Bustreo, S.; Mecca, C.; Spadi, R.; Fanchini, L.; Ritorto, G.; Zanini, M.; Ciuffreda, L.; Racca, P.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - ELETTRONICO. - 27 Issue supplementary 4:(2016), pp. 53-54. (Intervento presentato al convegno XVIII National Congress of Medical Oncology, 28-30 October 2016, Rome, Italy tenutosi a Roma nel 28-30 October 2016) [10.1093/annonc/mdw335.50].

Availability:

This version is available at: 11583/2655384 since: 2017-06-21T17:47:29Z

Publisher:

Oxford University

Published

DOI:10.1093/annonc/mdw335.50

Terms of use:

openAccess

This article is made available under terms and conditions as specified in the corresponding bibliographic description in the repository

Publisher copyright

(Article begins on next page)

The followiing Table resumes the main results of our survey:

Group	N- median age - % male	Characteristics	Benefits	G3 or G4 toxicities*
A) Cardiac comorbidities	6 pts – 70 years – 100% male	100% 1 st line, 50 % ECOG PS 1, 85,7% doublet	ORR 50% (2 pts not evaluable), CB 75%	33,3%
B) Older Age	2 pts – 82 years – 100% male	100% 1 st line, 100% monotherapy	ORR 50%, no SD	100%
C) Further line	24 pts – 64 years – 45,8% male	33,3% 4 th -6 th line, 54% ECOG PS 1, 50% doublet (45% TOMOX)	ORR 0% (3 pts not evaluable), CB 9,5% Relief from symptoms 25%	16,7%
Doublet = TOMOX or TOMIRI. ORR= overall response rate. CB = ORR + stable disease.				

Globally 11 patients (45,8%) had G0 or G1 toxicities while none experienced G3 renal failure from Raltitrexed.

Conclusions: the administration of Raltitrexed is a part of daily clinical practice at our center in patients with mCRC and cardiac comorbidities or older age with relevant efficacy but frequent severe toxicities. The use in the very advanced setting can bring a clinical benefit/relief from symptoms in up to 25% of patients but with severe toxicities in up to 17%.

Parole Chiave

1. Raltitrexed
2. Metastatic Colorectal Cancer
3. Safety

Co-autori

1. **Zaccaria Gian Maria** (Altro)
Dipartimento di Elettronica e Telecomunicazioni, Politecnico - Torino
2. **Bustreo Sara** (Medico - Età uguale o inferiore a 40 anni)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
3. **Mecca Caterina** (Medico - Età uguale o inferiore a 40 anni)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
4. **Spadi Rosella** (Medico - Età uguale o inferiore a 40 anni)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
5. **Fanchini Laura** (Medico)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
6. **Ritorto Giuliana** (Medico)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
7. **Zanini Marcello** (Medico)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
8. **Ciuffreda Libero** (Medico)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino
9. **Racca Patrizia** (Medico)
Colorectal Cancer Unit, Oncologia Medica 1, Città della Salute e della Scienza - Torino